Please login to the form below
Exelixis
This page shows the latest Exelixis news and features for those working in and with pharma, biotech and healthcare.
BMS eyes approval for second Opdivo combo in kidney cancer
Detailed results presented at ESMO 2020 virtual congress. Bristol Myers Squibb has reported positive data for a combination of its PD-L1 inhibitor Opdivo with Exelixis’ Cabometyx in renal cell carcinoma ... BMS and Exelixis have already completed their
Latest news
-
Merck gets first approval for MET inhibitor tepotinib in Japan
ArQule and Kyowa Hakko abandoned their MET inhibitor tivantinib in 2017 after a string of trial failures, while GlaxoSmithKline/Exelixis’ also seem to have dropped their MET/VEGF inhibitor foretinib and
-
Exelixis bounces back with new prostate cancer data
$725m and $775 this year, according to Exelixis’ recently reported financial guidance for 2020. ... Exelixis intends to file the cabozantinib/Tecentriq combination with the FDA for accelerated approval in metastatic CRPC by 2021.
-
Merck bulks up in cancer with $2.2bn Peloton buy
with Exelixis/Ipsen’s multikinase inhibitor Cabometyx (cabozantinib).
-
Merck’s Bavencio joins first-line kidney cancer face-off
Both combinations could challenge the position of Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab), which has started to replace Sutent and other TKIs like Exelixis’ Cabometyx (cabozantinib) as the ... Exelixis’ drug could also be
-
Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?
EUROPE. European approval for Cabometyx in RCC. The European Commission has approved Ipsen and Exelixis’ Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).
More from news
Approximately 5 fully matching, plus 23 partially matching documents found.
Latest Intelligence
-
Charting a course for expansion
Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis.
-
Deal Watch March 2016
Two deals involved products at a later stage of development: Dr Reddy's licence for Xenoport's phase II product XP23829 for plaque psoriasis, and Ipsen's licence for Exelixis's ... Collaboration – discovery, development &commercialisation. $965.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Exelixis appoints Andrew Peters to newly created position
He joins the biotech as its vice president, strategy. California, US-based biotechnology group Exelixis has appointed Andrew Peters as vice president of strategy. ... His familiarity with Exelixis and the biotech landscape should make for a seamless
-
Decibel Therapeutics expands leadership team
Prior to this, he was president and chief executive of Exelixis and served as president of Bayer Biotechnology, overseeing the business development, manufacturing and R&D of the company's biological
-
Frances Heller joins BMS senior management
Heller comes to BMS from Exelixis, a San Francisco-based genomics drug discovery company, where she was executive vice president of business development.
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Lilly’s Verzenio scores a win in early-stage breast cancer
- UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- Keytruda doubles five-year survival rate in NSCLC
- FDA approves Roche’s Actemra COVID-19 trial
PMHub
90TEN
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...
Latest intelligence
- Switzerland: a life sciences hub
- Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
- Responding to dynamic shifts in value communications
- OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
- Doing what we can and having fun doing it: our fundraising month
- Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...
Quick links
Infographics
